Kimzey A, Mihalchik A, Bottomley A, Wood M. Development of an occupational exposure limit (OEL) and permissible daily exposure (PDE) limit to support manufacturing of an intermediate antibody using read-across. Poster P413, American College of Toxicology (ACT) 47th Annual Meeting, San Antonio, TX, November 2026.
Abstract
Established approaches for deriving occupational exposure limits (OELs) and permissible daily exposures (PDEs) for small-molecule pharmaceuticals are well defined within applicable guidance (e.g., EMA Guideline on Setting Health-based Exposure Limits). However, harmonized approaches for largemolecule therapeutics remain limited, despite increased manufacturing of new modalities (e.g., monoclonal antibodies [mAbs], antibody–drug conjugates [ADCs], oligonucleotides). Although basic justification of OEL and PDE derivations has historically been accepted by some manufacturers, an expectation for more robust, data-driven support has been observed. This case study describes the derivation of an OEL and PDE for a mAb intermediate used in the manufacture of an ADC. ADC safety data were not considered relevant, as observed toxicities were driven primarily by the cytotoxic payload rather than the mAb. A read-across approach was therefore applied, integrating target expression in healthy and diseased tissues, absence of expression in respiratory tissues, off-target binding assessments, repeat-dose toxicity data from a surrogate antibody, and general large-molecule considerations (e.g., limited bioavailability via inhalation or dermal exposure and reduced environmental stability). A surrogate-derived PDE applicable to a general patient population over a lifetime of exposure was derived and extrapolated to an OEL. This approach demonstrates a pragmatic strategy for establishing limits for a data-poor large molecule and highlights evolving expectations for risk assessment in biopharmaceutical manufacturing.
